Melanotan II
Pending PCACAlso known as: MT-2, MTII
Melanocortin & Sexual HealthLast reviewed: April 28, 2026
A synthetic analog of alpha-MSH that acts on melanocortin receptors. Originally developed at the University of Arizona as a potential tanning agent, it gained notoriety for potent sexual arousal and appetite suppression effects.
Mechanism of Action
Activates MC1R (melanocortin 1 receptor) to stimulate melanin production. Also activates MC3R and MC4R, which mediate sexual arousal, appetite suppression, and cardiovascular effects. The MC4R activation is primarily responsible for its erectile and libido-enhancing properties.
Common Uses
- Skin tanning
- Sexual dysfunction treatment
- Libido enhancement
- Erectile dysfunction (investigational)
Known Risks
- Nausea and vomiting (common)
- Facial flushing
- Spontaneous and prolonged erections
- Melanocyte stimulation may activate existing moles or nevi
- Potential cardiovascular effects
- High abuse potential from gray market
- Very limited controlled clinical trial data
Regulatory Status
Removed from FDA 503A Category 2 effective April 22, 2026. Scheduled for PCAC review before February 2027. One of the more controversial compounds on the list due to its widespread gray-market use and safety concerns. Compounding not yet authorized — status is in regulatory gray zone pending PCAC recommendation.
Get notified when the PCAC decides on Melanotan II
Scheduled review: By February 2027. We'll email you the same day results are announced.
Common Protocols
Protocol information is for educational reference only. Dosing varies significantly by individual, condition, and physician guidance. Always work with a licensed healthcare provider.
Subcutaneous injection
Typical Dose
0.25–0.5 mg (loading), 0.5–1 mg (maintenance)
Frequency
Daily during loading, then as needed
Cycle Length
Loading: 1–2 weeks | Maintenance: as needed
Start very low (0.25 mg) to assess nausea tolerance. Tanning effects accumulate with UV exposure. Sexual effects typically onset within 1–2 hours of injection. High gray-market abuse potential — quality verification is critical.
Related Compounds
Research References
This information is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy. Data is compiled from published research and regulatory sources and may not reflect the most recent developments.